Company intelligence / Profile preview

Cadenza Bio

Oklahoma City, Oklahoma, United Statescadenza.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

Early animal studies show that their lead compound CAD-1 reduces motor disability, increases functional remyelination, and induces neuroprotection in MS models. The compound has shown therapeutic efficacy in preclinical animal models of MS and Endometriosis.

Therapeutic areas: Women's HealthNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

K110

Preclinical

Partnerships

University of Illinois Urbana-ChampaignUniversity of California Riverside

Beyond the preview

Go deeper on Cadenza Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cadenza Bio.

Explore the full profile